But the complement system is an oft-overlooked part of the immune system that could be exploited to create new therapies. It’s more than a decade since the first checkpoint inhibitor hit the ...

Earlier this year, Apellis Pharma became the first company to claim FDA approval for a drug to treat the condition, Syfovre (pegcetacoplan), which also targets the complement system. Syfovre needs ...